Pneumococcal Vaccines Market Size Share and Industry Outlook to 2028

SKU: DMBT10 | Last Updated On: Dec 16 2021 | No. of Pages: 180 | Available Formats

> Global Pneumococcal Vaccines Market Expected to reach a high CAGR of 8.30% By 2028: DataM Intelligence

Global Pneumococcal Vaccines Market is segmented By Product Type (Pneumococcal conjugate vaccine, Pneumococcal polysaccharide vaccine), By End-User (Infants/Young Children, Adults/ Young Adults, Geriatric), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028


Market Overview

The Global Pneumococcal Vaccines Market is expected to grow at a CAGR of 8.30% during the forecasting period (2021-2028).


  • Pneumococcal Vaccines help prevent pneumococcal disease, which is a type of infection caused by Streptococcus pneumonia bacteria.
  • Pneumococcal disease is contagious and can cause severe infections in the lungs, the lining of the brain, invasive pneumococcal disease, concomitant administration.
  • The spinal cord, and blood. It is more common in children, but it’s most likely to cause severe complications in adults.
  • Search for new vaccines is warranted as Streptococcus pneumonia has developed resistance to several available drugs.
  • The genome of Streptococcus pneumoniae has been identified to contain new drug sites, hence aiding in developing newer drugs to treat Pneumococcal diseases.

Recommended vaccines and doses

  • It is recommended that all children under age 2 be immunized with the pneumococcal conjugate vaccine (Prevnar 13®) in four doses spread out over slightly more than a year.
  • The PPSV23 vaccine that protects against 23 types of pneumococcal bacteria is administered to adults 65 years or older and for kids who are 2 years or older.

What’s trending in the Pneumococcal Vaccines market?

  • In 2017, demand for pneumococcal vaccines continued to increase.
  • Major factors that contributed to the demand include increasing prevalence of pneumonia globally,
  • post-marketing study
  • growing awareness, the rise in government focus on immunization programs for pneumonia, and the development of quality vaccines such as PPSV23.
  • Pneumococcal vaccine is a big market.
  • The bacteria Streptococcus pneumoniae is one the most frequent enabler of morbidity and mortality worldwide.
  • As such, the adult market for pneumococcal vaccines is quite perennial.

Market Growth Analysis

  • This report segments the pneumococcal vaccines market by product type, dosage, end-user, and region.
  • Based on product type, the market is classified into two categories, namely pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine.
  • Pneumococcal conjugate vaccines are newer while the pneumococcal polysaccharide or concomitant administration. The unconjugated vaccine is the older ones.
  • Based on end-user, the market is segmented into Infants/Young Children (2-10 Age), Young Adults/Adults (10-64 Age), and Geriatric (Over 65 Age).
  • Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
  • Globally North America is the largest market for pneumococcal vaccines with significant demand concentrated in the US owing to the high incidence of infections caused by the pneumococcal disease every year in the US, with over 50,000 cases of pneumococcal bacteremia.

CDC recommends pneumococcal vaccination for all children under two years and all adults 65 years or older, hence driving the demand for PCV vaccines.

Market Analysis

The report profiles the following companies in the Pneumococcal Vaccines market – Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline Plc., Sanofi Pasteur, Astellas Pharma Inc, and Serum Institute of India Pvt. Ltd.

By Product Type

  • Pneumococcal conjugate vaccine
  • Pneumococcal polysaccharide vaccine

By End-User

  • Infants/Young Children (2-10 Age)
  • Adults/ Young Adults (10-64 Age)
  • Geriatric (Over 65 Age)

By Region

  • Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
  • Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
  • North America (The USA, Canada, Mexico)
  • South America (Brazil, Argentina, Rest of South America)
  • Rest of the World

Reasons for purchasing this report?

  • Visualize the composition of the Pneumococcal Vaccines market across each indication, regarding type and treatment options, highlighting the critical commercial assets and players.
  • Premium Market Growth Analysis
  • Identify commercial opportunities in the Pneumococcal Vaccines market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the market – level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for crucial Pneumococcal Vaccines of all major market players.

Who are the key vendors in the global pneumococcal vaccine market?

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Trending Topics

Monoclonal Antibody Therapeutics Market

Precision Medicine Market

Preventive Vaccine Market


Table of Contents

1. Pneumococcal Vaccines Market – Methodology and Scope

1.1 Research Methodology

1.2 Scope of the Report

2. Pneumococcal Vaccines Market – Industry Trends

2.1 Key Trends & Developments

3. Pneumococcal Vaccines Market – Market Outlook

3.1 Market Drivers

3.1.1 The rise in government focus on immunization programs for pneumonia

3.1.2 Development of quality vaccines such as PPSV23

3.2 Market Restraints

3.2.1 The Higher cost associated with the development of these vaccines

3.2.2.Longer timelines required for their production

3.3 Threats and Opportunities

3.4 Porter’s 5 Forces

4. Product-based Analysis

4.1 By Product Type

4.1.1 Pneumococcal conjugate vaccine

4.1.2 Pneumococcal polysaccharide vaccine

4.2 By End-User

4.2.1 Infants/Young Children (2-10 Age)

4.2.2 Adults/ Young Adults (10-64 Age)

4.2.3 Geriatric (Over 65 Age)

5. Regional, Country-level Analysis

5.1. North America

5.1.1. The USA

5.1.2. Canada

5.1.3. Mexico

5.2. Europe

5.2.1. Germany

5.2.2. France

5.2.3. The UK

5.2.4. Italy

5.2.5. Spain

5.2.6. Rest of Europe

5.3. Asia Pacific

5.3.1. China

5.3.2. Japan

5.3.3. India

5.3.4. Australia

5.3.5. Rest of Asia Pacific

5.4. South America

5.4.1. Brazil

5.4.2. Argentina

5.4.3. Rest of South America

5.5 Rest of the World

6. Competitive Trends

6.1. Market Share Analysis

6.2. Mergers and Acquisitions Analysis

6.3. New Product Launches

7. Company Profiles

7.1 Merck & Co., Inc.

7.2 Pfizer Inc.

7.3 GlaxoSmithKline Plc.

7.4 Sanofi Pasteur

7.5 Astellas Pharma Inc

7.6 Serum Institute of India Pvt. Ltd. 

8. Appendix

8.1 Sources

8.2 List of Tables

8.3 Expert Panel Validation

8.4 Disclaimer

8.5 Contact Us

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Year-End Offer from
DataM Intelligence

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!